Instability Mechanism of Osimertinib in Plasma and a Solving Strategy in the Pharmacokinetics Study

• Autori principali: Zheng Yuan (Autore), Xin Yu (Autore), Siyang Wu (Autore), Xiaonan Wu (Autore), Qiutao Wang (Autore), Wenhao Cheng (Autore), Weiyu Hu (Autore), Chen Kang (Autore), Wei Yang (Autore), Yingfei Li (Autore), Xiao-Yang Zhou (Autore)
• Natura: Libro
• Pubblicazione: Frontiers Media S.A., 2022-07-01T00:00:00Z.
• Soggetti: article
• Accesso online: Connect to this object online.

Osimertinib is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) and a star medication used to treat non-small-cell lung carcinomas (NSCLCs). It has caused broad public concern that osimertinib has relatively low stability in plasma. We explored why osimertinib...